Drug-induced interstitial lung disease
Overview
Drug-induced ILD (DI-ILD) is one of the few reversible causes of ILD - early drug withdrawal is critical. Presentation is often indistinguishable from other ILD subtypes; diagnosis is one of exclusion.
Presentation
•Progressive dyspnoea - initially on exertion, later at rest
•Dry cough - non-productive
•Fine bibasal end-inspiratory (Velcro) crackles - do not clear on coughing
•Fever - more common in immune-mediated reactions (methotrexate, nitrofurantoin)
•Digital clubbing - sign of established fibrosis
Investigations
🥇 First-line
•Chest X-ray - bilateral reticular/ground-glass shadowing, lower zones; may be normal early
•Spirometry - restrictive pattern (FEV1/FVC >0.7, reduced FVC); reduced DLCO is earliest and most sensitive abnormality
•FBC - eosinophilia (nitrofurantoin, methotrexate); lymphopenia with cytotoxics
•Autoimmune screen (ANA, ANCA, RF, anti-CCP, ENA, Scl-70) - to exclude CTD-associated ILD
🏆 Gold standard
•HRCT thorax - ground-glass opacity, reticulation, traction bronchiectasis, honeycombing; amiodarone causes characteristic high-attenuation opacities
🥈 Second-line
•BAL - lymphocytosis (drug hypersensitivity), eosinophilia (eosinophilic pneumonia), foamy macrophages (amiodarone); also excludes infection
•Lung biopsy - reserved for diagnostically uncertain cases
Management
•Withdraw the causative drug promptly - even before histological confirmation; continued exposure risks irreversible fibrosis
•Stopping amiodarone requires cardiology input (risk of refractory arrhythmia); note long half-life means toxicity may persist after withdrawal
•Prednisolone - used for immune-mediated reactions (e.g. methotrexate hypersensitivity, amiodarone toxicity) to accelerate recovery
Prognosis
Prognosis by mechanism
| Pattern | Example drugs | Prognosis |
|---|---|---|
| Immune-mediated | Methotrexate, nitrofurantoin | Good - most recover full/near-full lung function after withdrawal ± steroids |
| Direct cytotoxic | Bleomycin, cyclophosphamide | Higher risk of permanent fibrosis, especially if delayed diagnosis |
| Combined toxic/inflammatory | Amiodarone | Intermediate - recovery slow/incomplete in established fibrosis; toxicity may worsen briefly after stopping due to long half-life |
Key culprit drugs and mechanisms
High-yield drug causes of ILD
| Drug | Mechanism | Distinguishing feature |
|---|---|---|
| Amiodarone | Toxic + inflammatory (phospholipidosis) | High-attenuation opacities on HRCT (iodine); foamy macrophages on BAL; very long half-life - toxicity may persist/worsen after stopping |
| Methotrexate | Immune-mediated (granulomatous hypersensitivity) | Fever common; lymphocytosis on BAL; good prognosis with withdrawal ± steroids |
| Nitrofurantoin | Immune-mediated (eosinophilic pneumonitis) | Acute onset (days); eosinophilia on FBC/BAL; good prognosis |
| Bleomycin | Direct cytotoxic (reactive oxygen species) | Sensitises lung to O2 toxicity - even years later; higher risk of permanent fibrosis |
| Cyclophosphamide | Direct cytotoxic | Higher risk of irreversible fibrosis, especially if diagnosis delayed |
Monitoring and prevention
•Baseline HRCT and PFTs (including DLCO) before starting bleomycin or cyclophosphamide
•Annual CXR and PFTs for patients on long-term amiodarone
•DLCO decline >15-20% from baseline on methotrexate - prompt drug cessation and specialist review
•Avoid high-dose oxygen in patients who have received bleomycin